PDF(Pubmed)
Abstract：
UNASSIGNED: To observe the vascular development results of tertiary anti-vascular endothelial growth factor (anti-VEGF) therapy following spontaneous second reactivation of retinopathy of prematurity (ROP).
UNASSIGNED: This retrospective study included 22 infants (42 eyes) with Type 1 or aggressive ROP (A-ROP) who received three anti-VEGF drug treatments for ROP from January 2018 to December 2022. The vascular growth, possible associated risk factors, and the retinal vascularization (DB/DF ratio) were assessed.
UNASSIGNED: The mean follow-up was 17.6 months. After the 3rd intravitreal injection, seven eyes showed complete vascularization (Group 1), while the remaining 35 eyes demonstrated persistent avascular retina (PAR) (Group 2). In Group 2, 17 eyes maintained a stable state and were classified in the regression subgroup. The other 18 eyes developed a 3rd reactivation (reactivation subgroup) and were treated with laser photocoagulation (LPC).Birth weight (BW) was significantly lower in Group 2 than in Group 1 (p < 0.001). The decision tree analysis shows that only infants weighing more than 1,250 g (17.50%) had a chance to achieve complete retinal vascularization. The possibility of PAR was higher in patients with BW <1,250 g than ≥1,250 g (70.00% vs. 12.50%). In addition, most infants with BW ≥ 1,290 g and initial ROP disease in Zone I or posterior Zone II developed PAR.
UNASSIGNED: Tertiary IVR can successfully treat a second ROP reactivation and improve peripheral retinal vascularization. BW is the most significant factor related to complete retinal vascularization. Our decision tree model may be helpful in predicting the prognosis of anti-VEGF drugs in the event of a second ROP reactivation.
UNASSIGNED: This retrospective study included 22 infants (42 eyes) with Type 1 or aggressive ROP (A-ROP) who received three anti-VEGF drug treatments for ROP from January 2018 to December 2022. The vascular growth, possible associated risk factors, and the retinal vascularization (DB/DF ratio) were assessed.
UNASSIGNED: The mean follow-up was 17.6 months. After the 3rd intravitreal injection, seven eyes showed complete vascularization (Group 1), while the remaining 35 eyes demonstrated persistent avascular retina (PAR) (Group 2). In Group 2, 17 eyes maintained a stable state and were classified in the regression subgroup. The other 18 eyes developed a 3rd reactivation (reactivation subgroup) and were treated with laser photocoagulation (LPC).Birth weight (BW) was significantly lower in Group 2 than in Group 1 (p < 0.001). The decision tree analysis shows that only infants weighing more than 1,250 g (17.50%) had a chance to achieve complete retinal vascularization. The possibility of PAR was higher in patients with BW <1,250 g than ≥1,250 g (70.00% vs. 12.50%). In addition, most infants with BW ≥ 1,290 g and initial ROP disease in Zone I or posterior Zone II developed PAR.
UNASSIGNED: Tertiary IVR can successfully treat a second ROP reactivation and improve peripheral retinal vascularization. BW is the most significant factor related to complete retinal vascularization. Our decision tree model may be helpful in predicting the prognosis of anti-VEGF drugs in the event of a second ROP reactivation.
摘要：
■观察三级抗血管内皮生长因子（抗VEGF）治疗早产儿视网膜病变（ROP）自发二次再激活后的血管发育结果。
这项回顾性研究包括22名1型或侵袭性ROP（A-ROP）婴儿（42只眼），他们从2018年1月至2022年12月接受了三种抗VEGF药物治疗。血管生长，可能的相关风险因素，评估视网膜血管形成(DB/DF比)。
■平均随访17.6个月。第三次玻璃体内注射后,7只眼显示完全血管化（第1组），而其余35只眼表现出持续性无血管视网膜（PAR）（第2组）。在第2组中，17只眼保持稳定状态，并被分类为回归亚组。其他18只眼发生了第三次再激活（再激活亚组），并接受了激光光凝（LPC）治疗。第2组的出生体重(BW)显著低于第1组(p<0.001)。决策树分析表明，只有体重超过1,250g（17.50％）的婴儿才有机会实现完全的视网膜血管化。BW<1,250g的患者PAR的可能性高于≥1,250g（70.00％vs.12.50%）。此外,大多数BW≥1,290g且I区或II区初始ROP疾病的婴儿发展为PAR。
■三级IVR可以成功治疗第二次ROP再激活并改善周边视网膜血管形成。BW是与完全视网膜血管化有关的最重要的因素。我们的决策树模型可能有助于在第二次ROP再激活的情况下预测抗VEGF药物的预后。
这项回顾性研究包括22名1型或侵袭性ROP（A-ROP）婴儿（42只眼），他们从2018年1月至2022年12月接受了三种抗VEGF药物治疗。血管生长，可能的相关风险因素，评估视网膜血管形成(DB/DF比)。
■平均随访17.6个月。第三次玻璃体内注射后,7只眼显示完全血管化（第1组），而其余35只眼表现出持续性无血管视网膜（PAR）（第2组）。在第2组中，17只眼保持稳定状态，并被分类为回归亚组。其他18只眼发生了第三次再激活（再激活亚组），并接受了激光光凝（LPC）治疗。第2组的出生体重(BW)显著低于第1组(p<0.001)。决策树分析表明，只有体重超过1,250g（17.50％）的婴儿才有机会实现完全的视网膜血管化。BW<1,250g的患者PAR的可能性高于≥1,250g（70.00％vs.12.50%）。此外,大多数BW≥1,290g且I区或II区初始ROP疾病的婴儿发展为PAR。
■三级IVR可以成功治疗第二次ROP再激活并改善周边视网膜血管形成。BW是与完全视网膜血管化有关的最重要的因素。我们的决策树模型可能有助于在第二次ROP再激活的情况下预测抗VEGF药物的预后。
